Palisade Bio Participates in Virtual Investor “What This Means” Segment
Provided By GlobeNewswire
Last update: Mar 4, 2025
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
0.6785
-0.01 (-1.7%)
Find more stocks in the Stock Screener
PALI Latest News and Analysis
